Haemate P

Haemate P is a prescription medication that contains human coagulation factor VIII and von Willebrand factor. It is supplied for intravenous administration and is used to replace deficient clotting proteins in patients with hemophilia A or von Willebrand disease. The product is marketed in the European Union and is classified as a coagulation factor replacement therapy.

Haemate P is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies. It is used in both prophylactic and on‑demand treatment settings.

- Treatment of acute bleeding episodes in hemophilia A patients. - Routine prophylaxis to prevent spontaneous bleeds in hemophilia A. - Management of bleeding episodes in von Willebrand disease. - Perioperative hemostatic support for surgical procedures in patients with these disorders. - Replacement therapy in patients with combined factor VIII and von Willebrand factor deficiency.

Side effects of Haemate P vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common: - Headache - Fever or chills - Nausea or vomiting - Injection site reactions such as redness or swelling - Mild hypertension - Transient increase in liver enzymes

Serious: - Development of inhibitors (antibodies) against factor VIII - Anaphylactic or severe allergic reactions - Thromboembolic events (blood clots) - Severe hypertension or hypertensive crisis

Before using Haemate P, certain precautions should be considered to ensure safe administration.

- Assess for a history of inhibitors to factor VIII or von Willebrand factor. - Monitor for signs of allergic reactions during infusion. - Use caution in patients with cardiovascular disease or a history of thrombosis. - Evaluate liver and renal function prior to initiating therapy. - Adjust dosing in pediatric patients based on weight and clinical response. - Ensure proper aseptic technique to prevent contamination of the intravenous line.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concurrent use of other clotting factor concentrates without medical supervision. - High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor replacement. - Immunosuppressive therapies that may alter inhibitor development. - Medications that affect blood pressure, such as vasoconstrictors. - Live vaccines, due to potential immune modulation.